New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.

DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced a significant advancement in access to its products for those treating ...

Late Monday, the agency overseeing Medicare and Medicaid proposed $4.5 billion of spending cuts for home healthcare, and new economies on diabetes devices. The spending cuts are another problem for ...

Feb 12 (Reuters) - Medical device maker Dexcom beat Wall Street estimates for fourth-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring systems. The company ...

March 24--Shares of DexCom gained more than 8 percent Friday after Medicare issued a favorable ruling for reimbursing use of continuous glucose monitors, made by the San Diego-based company. DexCom ...